Bittensor (TAO) is forming a textbook falling wedge on the daily chart as of Monday, February 10, 2026, signaling a potential bullish reversal, according to theBittensor (TAO) is forming a textbook falling wedge on the daily chart as of Monday, February 10, 2026, signaling a potential bullish reversal, according to the

Bittensor (TAO) Price Targets $500 Reversal after Falling Wedge Formation

2026/02/10 11:30
3분 읽기

Bittensor (TAO) is forming a textbook falling wedge on the daily chart as of Monday, February 10, 2026, signaling a potential bullish reversal, according to the crypto analyst Satoshi Flipper. 

Trading near its all-time lows, the token has attracted attention as a high-reward opportunity. Satoshi Flipper notes that the RSI has dropped to historic lows, highlighting extreme oversold conditions that could precede a sharp upward move.

Source: Satoshi Flipper X Post

A breakout above the wedge’s upper trendline could trigger significant gains, with targets around $500, representing a potential 3X move. 

While technical patterns are not guarantees, the combination of historic lows, oversold momentum, and a classic bullish formation makes TAO a key watchlist candidate. Traders are advised to monitor price action closely for confirmation.

Also Read: Bittensor (TAO) Tests Key Support and Eyes $300 Bounce Amid Falling Wedge

TAO Approaches 1.618 Fibonacci Extension Level

According to TradingView, as of Monday, February 9, after reaching its peak in early January 2026, the price attempted to correct but failed to stay above these key Fibonacci points. 

Resistance is at 0.236 ($279.54), 0.382 ($265.54), 0.5 ($254.23), and 0.618 ($242.91), where it temporarily rested or reversed back from. The initial drop also points to an ongoing downtrend, as evidenced by consecutive red candles.

Source: TradingView

Currently, the price has moved past the 1.0 Fibonacci level, which is at $206.28, and is close to reaching the 1.618 level, which is at $147.02, indicating that bearish momentum is still strong. 

There is a minor consolidation phase at $160-$165, but this does not confirm anything. Overall, it appears that selling pressure is still strong, and prices can continue to fall even further.

RSI and MACD Signal Persistent Bearish Pressure

The RSI currently stands at 28.65, dipping below the oversold line at 30. This shows a period of increased selling activity. While the small increase may indicate a slight recovery or a period of consolidation, the asset is currently oversold. 

The 14-period moving average currently stands at 32.18, showing a weak trend but also a period where the asset may stabilize, though short-term selling activity may dominate the trend.

Source: TradingView

The MACD also indicates bearish conditions. The MACD line is at -23.77, which is lower than the signal line at -19.55. The histogram is also negative at -4.22. 

It indicates that selling is still ongoing. However, the recent small negative bars suggest that the rate at which selling is declining is slowing down, suggesting that it might turn around in the short term.

Also Read: Bittensor (TAO) Price Stalls Near $191 as Support–Resistance Range Tightens

시장 기회
Bittensor 로고
Bittensor 가격(TAO)
$157.77
$157.77$157.77
-0.27%
USD
Bittensor (TAO) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, service@support.mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

추천 콘텐츠

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
공유하기
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
공유하기
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
공유하기
BitcoinEthereumNews2025/09/18 05:26